Business & Technology Briefs (03/2007)
Brief summaries of recent product and clinical developments in the device industry, including developments in Cardiac and Peripheral Devices, Miniature Robotic Devices, and Diabetes Management.
You may also be interested in...
Recent safety issues with drug-eluting stents may have opened the door ever so slightly for cardiac surgeons and coronary artery bypass graft (CABG) surgery to stage a small but noticeable comeback in the treatment of coronary artery disease.
The recent diabetes alliance between Bristol-Myers Squibb and AstraZeneca on two late-stage clinical compounds highlights some of the different ways pharmaceutical companies are embracing both specialty products and externalization strategies to address the industry's growing pipeline problem. BMS and AZ are pursuing different approaches but in diabetes, those strategies are complementary: AZ's unabashed externalization and muscular primary care marketing suits BMS's gradual weaning off the blockbuster model.
According to Medtech Insight’s recently published report, US Markets for Neurostimulation Products, the frontier for neural stimulation is expanding rapidly, representing a $628 million market in 2006 that is forecast to grow by over 20% each year to produce sales approaching $2 billion in 2012. Topics discussed include implantable pulse generators, device reimbursement, and current and emerging applications for neurostimulation.